Authors: Kow CS, Hasan SS, Thiruchelvam K.
DOI: 10.3390/arm94010002
Abstract Summary
Carbocisteine (1500 mg/day) significantly reduces COPD exacerbations by 40% compared to placebo, according to a meta-analysis of four trials with 1,746 patients. The mucolytic agent works by improving mucus clearance, reducing inflammation and oxidative stress, while showing no increase in adverse events. This evidence supports its use as safe adjunctive therapy for COPD patients with frequent exacerbations.
Why Brain? ๐ง
Carbocisteine significantly cuts COPD exacerbation rates by 0.40/year vs placebo with no added adverse events, supporting its safe use as adjunctive therapy in high-risk patients.
Study Limitations:
Study limitations were not specified in the abstract.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
